In-house antibody Abgent emphasizes in-house production of most antibodies to ensure specificity, affinity, and reproducibility, highlighting a potential upsell of premium or custom antibodies and validated reagents for drug discovery projects.

Autophagy focus With over 1,000 new antibodies released annually and a focus on autophagy, stem cells, and neurodegeneration, there is a sales opportunity to align with teams researching these areas, offering latest autophagy rapid screening kits and related validation services.

Premium line The Crown line of premium antibodies and evaluation size vials for over 10,000 products present upsell potential for large-scale screening programs, catalogs, and procurement partnerships seeking high-quality, validated reagents.

Service expansion Abgent offers custom antibody development, peptide synthesis, and protein expression; pitch integrated custom services for customers needing end-to-end solutions, including difficult peptide synthesis and rapid turnaround.

Partnership readiness As a WuXi AppTec company with a scalable infrastructure and global web presence, Abgent is positioned to collaborate on broad research programs, external collaborations, and cross-sell opportunities within WuXi’s ecosystem.